We have previously characterized diverse models of stable resistance to either BRAFV600 inhibitor vemurafenib or MEK1/2 inhibitor trametinib obtained from patient-derived drug-naïve melanoma cell lines by long-term treatment with increasing concentrations of drugs [22]. This evidence concerns the gene MAP2K1 and melanoma.